Prevention of Meningococcal Disease: Current Use of Polysaccharide and Conjugate Vaccines
Invasive meningococcal disease (IMD) is a serious public health threat, characterized by rapid symptom onset and high fatality rate, even after treatment. Efforts to prevent IMD remain challenging, because there is neither an immunogenic vaccine for infants nor a vaccine to prevent serogroup B disease that is currently licensed. This article, published in Clinical Infectious Diseases, summarizes current US recommendations for vaccine prevention of meningococcal disease and strategies to improve vaccine coverage among adolescents.
Author(s): Poland GA
Download file (English)
363 KB PDF (Located at www.journals.uchicago.edu)
Citation: Poland GA. Prevention of Meningococcal Disease: Current Use of Polysaccharide and Conjugate Vaccines. Clinical Infectious Diseases. 2010;50(Supplement 2):S45-53.